ADVENT ACCESS ACQUIRES Vwing™ VASCULAR NEEDLE GUIDE FROM VITAL ACCESS TO CREATE LEADING PORTFOLIO OF VASCULAR ACCESS SOLUTIONS FOR DIALYSIS
October 04, 2018 06:00 ET
|
Advent Access
Singapore, Oct. 04, 2018 (GLOBE NEWSWIRE) -- -- Advent’s IP portfolio now one of the industry’s most extensive in technology-assisted use of AV fistulas-- Acquisition provides access to key US...
ADVENT ACCESS COMPLETES CE MARK SUBMISSION FOR av-GuardianTM
September 20, 2018 06:00 ET
|
Advent Access
Singapore, Sept. 20, 2018 (GLOBE NEWSWIRE) -- Singapore, 20 September 2018 – Advent Access (Advent), one of Singapore’s most innovative medtech companies, today announced that it has...
Proteon Therapeutics to Present at the JMP Securities Life Sciences Conference June 22nd
June 15, 2016 08:00 ET
|
Proteon Therapeutics, Inc.
WALTHAM, Mass., June 15, 2016 (GLOBE NEWSWIRE) -- Proteon Therapeutics Inc. (Nasdaq:PRTO), a company developing novel, first-in-class therapeutics to address the medical needs of patients...
U.S. FDA Approves Rockwell’s Triferic® Powder Packet for Treating Anemia in Hemodialysis Patients
April 26, 2016 08:00 ET
|
Rockwell Medical, Inc.
WIXOM, Mich., April 26, 2016 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (NASDAQ:RMTI), a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney...
Proteon Therapeutics Announces Positive Long-Term Results From Phase 2 Study of Investigational New Drug Vonapanitase in Chronic Kidney Disease Patients Undergoing Surgical Creation of an Arteriovenous Fistula for Hemodialysis
March 26, 2015 19:00 ET
|
Proteon Therapeutics, Inc.
DALLAS and WALTHAM, Mass., March 26, 2015 (GLOBE NEWSWIRE) -- Proteon Therapeutics Inc. (Nasdaq:PRTO), a company developing novel, first-in-class therapeutics to address the medical needs of...
Deltanoid's DP001 (2MD) pharmaceutical demonstrated safe and effective in kidney failure patients on dialysis
October 15, 2014 11:39 ET
|
Wisconsin Alumni Research Foundation
MADISON, Wis., Oct. 15, 2014 (GLOBE NEWSWIRE) -- Deltanoid Pharmaceuticals announces the successful completion of a phase 2B clinical trial for its lead experimental drug DP001 for the treatment of...